Denali Therapeutics Inc.DNLINASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+6.6%
5Y CAGR+14.8%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+6.6%/yr
vs +26.5%/yr prior
5Y CAGR
+14.8%/yr
Recent deceleration
Acceleration
-19.9pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $544.16M | +11.7% |
| 2024 | $487.34M | -7.6% |
| 2023 | $527.23M | +17.4% |
| 2022 | $449.21M | +30.4% |
| 2021 | $344.41M | +26.2% |
| 2020 | $272.94M | +13.8% |
| 2019 | $239.86M | +36.6% |
| 2018 | $175.53M | +94.7% |
| 2017 | $90.14M | +3.1% |
| 2016 | $87.43M | - |